Accedi

Bibliografie tematiche / Drug Resistance / Articoli di riviste

Segui questo link per vedere altri tipi di pubblicazioni sul tema: Drug Resistance.

Articoli di riviste sul tema "Drug Resistance"

Autore: Grafiati

Pubblicato: 4 giugno 2021

Ultima modifica: 2 novembre 2024

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "Drug Resistance".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.

1

K, Tiwari. "Drug Resistance: Challenges and Updates". Journal of Natural & Ayurvedic Medicine 3, n. 3 (15 luglio 2019): 1–2. http://dx.doi.org/10.23880/jonam-16000196.

Testo completo

Abstract (sommario):

Use of antibiotics increased dramatically in last two decades. To cure most of the diseases broad spectrum antibiotics given. Human society and healthcare is going in wrong direction. One way the pharmaceutical companies are making huge money from it. The other way around is the overuse of these antibiotics, by patients knowing or unknowingly, not only making pathogens adapted but also the normal flora organisms becoming pathogens in coming future? Present article highlight the issues and possible solution of the present scenario.

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Singh, Amresh Kumar. "Resistance patterns and trends of extensively drug-resistant tuberculosis: 5-year experience". Journal of Microbiology and Infectious Diseases 03, n. 04 (1 dicembre 2013): 169–75. http://dx.doi.org/10.5799/ahinjs.02.2013.04.0103.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Dyary, Hiewa Othman. "Veterinary Anthelmintics and Anthelmintic Drug Resistance". Journal of Zankoy Sulaimani - Part A 18, n. 1 (12 novembre 2015): 191–206. http://dx.doi.org/10.17656/jzs.10463.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Çelik, Cem. "Increasing antimicrobial resistance in nosocomial pathogens; multidrug-resistant extensively drug-resistant and pandrug-resistant Acinetobacter baumannii". Journal of Microbiology and Infectious Diseases 4, n. 1 (1 marzo 2014): 7–12. http://dx.doi.org/10.5799/ahinjs.02.2014.01.0116.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Giaccone, Giuseppe, e Herbert M. Pinedo. "Drug Resistance". Oncologist 1, n. 1-2 (febbraio 1996): 82–87. http://dx.doi.org/10.1634/theoncologist.1-1-82.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Hochhauser, D., e A. L. Harris. "Drug resistance". British Medical Bulletin 47, n. 1 (1991): 178–96. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072454.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Prichard, R. K. "Drug resistance". International Journal for Parasitology 29, n. 1 (gennaio 1999): 137–38. http://dx.doi.org/10.1016/s0020-7519(98)00191-x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Texidó, Gemma, e Jürgen Moll. "Drug resistance". Drug Discovery Today: Technologies 11 (marzo 2014): 1–3. http://dx.doi.org/10.1016/j.ddtec.2014.03.013.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Köser, Claudio U., Babak Javid, Kathleen Liddell, Matthew J. Ellington, Silke Feuerriegel, Stefan Niemann, Nicholas M. Brown et al. "Drug-resistance mechanisms and tuberculosis drugs". Lancet 385, n. 9965 (gennaio 2015): 305–7. http://dx.doi.org/10.1016/s0140-6736(14)62450-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Coen, Donald M., e Richard J. Whitley. "Antiviral drugs and antiviral drug resistance". Current Opinion in Virology 1, n. 6 (dicembre 2011): 545–47. http://dx.doi.org/10.1016/j.coviro.2011.10.024.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

11

Hall, Andrew G., e Julie Irving. "New drugs, new drug resistance mechanisms". Expert Review of Anticancer Therapy 2, n. 3 (giugno 2002): 239–340. http://dx.doi.org/10.1586/14737140.2.3.239.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

12

Kumar, Saurabh, e Richa Prasad Mahato. "DRUG RESISTANCE AND RESISTANCE REVERSAL STRATEGIES IN MALARIA PARASITE". Journal of microbiology, biotechnology and food sciences 13, n. 5 (5 febbraio 2024): e10384. http://dx.doi.org/10.55251/jmbfs.10384.

Testo completo

Abstract (sommario):

The public health care system is currently facing a major problem with malaria. Globally, malarial deaths have decreased by an estimated 40% in the past two decades because of the clinically effective drugs (artemisinin-based combination therapies) against Plasmodium falciparum. In recent years, P falciparum develop resistance against all antimalarial drugs and then becomes developed multidrug resistance that a major challenge. Even though drug discovery programs have made substantial progress in the past decade, the potential for new drugs/combinations to improve the effectiveness of current malaria control strategies. Beyond, we have compiled a comprehensive review of clinically approved anti-malarial drugs with resistance mechanisms and a novel drug-resistance reversal approach in one place to meet this demand. The review aimed to provide detailed information on drug resistance, its regulatory molecular mechanisms responsible for resistance, and the novel available treatment of malaria. In this review, the article will help in developing effective interventions, potential approaches, and strategies to handle antimalarial resistance. This will prevent life-threatening infections.

Gli stili APA, Harvard, Vancouver, ISO e altri

13

Yusuf, Yenni. "ANTI-MALARIAL DRUG RESISTANCE". Majalah Kedokteran Andalas 37, n. 1 (3 maggio 2015): 64. http://dx.doi.org/10.22338/mka.v37.i1.p64-69.2014.

Testo completo

Abstract (sommario):

AbstrakTujuan studi ini adalah untuk menjelaskan mekanisme resistensi parasit malaria danusaha-usaha yang dapat dilakukan untuk menghadapi munculnya strain parasit yangresisten terhadap artemisinin. Metode yang digunakan adalah studi kepustakaan. ResistensiP.falciparum terhadap obat-obat anti malaria disebabkan oleh perubahan spontan yangterjadi pada beberapa gen seperti P.falciparum multi drug resistance1 (Pfmdr1), P.falciparumchloroquine transporter (Pfcrt), P.falciparum dihydropteroate synthase (Pfdhps), P.falciparumdihydrofolate reductase (Pfdhfr), and P.falciparum multidrug resistance-associated proteins(Pfmrp). Penyebaran resistensi tersebut dipengaruhi oleh tingkat transmisi di sebuah wilayah.WHO telah menjalankan usaha untuk menanggulangi penyebaran resistensi tersebut misalnyadengan merekomendasikan penghentian monoterapi artemisinin, dan pemberian anti malariasetelah konfirmasi laboratorium. Selain itu, perlu adanya penggunaan obat kombinasi, produksirejimen dosis tetap, dan pengembangan obat anti malaria baru. Kesimpulan dari hasil studiini ialah munculnya malaria resisten terhadap artemisinin akan menghambat usaha eradikasimalaria karena itu diperlukan usaha-usaha untuk menanggulanginya.AbstractThe objective of this study was to describe the development of anti-malarial drug resistanceof the parasites and the efforts taken to contain the emergence of artemisinin resistant malaria.This was a literature study. The development of resistance to anti-malarial drugs are due tospontaneous changes in certain genes such as of P.falciparum multi drug resistance1 (Pfmdr1),P.falciparum chloroquine resistance transporter (Pfcrt), P.falciparum dihydropteroate synthase(Pfdhps), P.falciparum dihydrofolate reductase (Pfdhfr), and P.falciparum multidrug resistanceassociatedproteins (Pfmrp). The spread of the resistance depends on the transmission ratewithin each area. WHO has established a global plan to contain the spread of this resistance,such as recommendation to withdraw artemisinin-based monotherapies and administrationof treatment after laboratory confirmation. In addition, administration of anti-malarial drugcombination, production of fixed dose regimen and development of new drugs are necessary.The Conclusion is emergence of artemisinin resistant malaria will threaten malaria eradicationthus some efforts are necessarily needed to contain it.Afiliasi penulis: Bagian Parasitologi Fakultas Kedokteran Universitas Hasanudin

Gli stili APA, Harvard, Vancouver, ISO e altri

14

Nyce, J., S. Leonard, D. Canupp, S. Schulz e S. Wong. "Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance." Proceedings of the National Academy of Sciences 90, n. 7 (1 aprile 1993): 2960–64. http://dx.doi.org/10.1073/pnas.90.7.2960.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

15

Hossain, Chowdhury Mobaswar, Lisa Kathleen Ryan, Meeta Gera, Sabyasachi Choudhuri, Nazmun Lyle, Kazi Asraf Ali e Gill Diamond. "Antifungals and Drug Resistance". Encyclopedia 2, n. 4 (10 ottobre 2022): 1722–37. http://dx.doi.org/10.3390/encyclopedia2040118.

Testo completo

Abstract (sommario):

Antifungal drugs prevent topical or invasive fungal infections (mycoses) either by stopping growth of fungi (termed fungistatic) or by killing the fungal cells (termed fungicidal). Antibiotics also prevent bacterial infections through either bacteriostatic or bactericidal mechanisms. These microorganisms successfully develop resistance against conventional drugs that are designed to kill or stop them from multiplying. When a fungus no longer responds to antifungal drug treatments and continues to grow, this is known as antifungal drug resistance. Bacteria have an amazing capacity to become resistant to antibiotic action as well, and the effectiveness of the scarce antifungal arsenal is jeopardised by this antibiotic resistance, which poses a severe threat to public health.

Gli stili APA, Harvard, Vancouver, ISO e altri

16

Perfect, John R., e Gary M. Cox. "Drug resistance in Cryptococcus neoformans". Drug Resistance Updates 2, n. 4 (agosto 1999): 259–69. http://dx.doi.org/10.1054/drup.1999.0090.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

17

Kennedy, David A., e Andrew F. Read. "Why does drug resistance readily evolve but vaccine resistance does not?" Proceedings of the Royal Society B: Biological Sciences 284, n. 1851 (29 marzo 2017): 20162562. http://dx.doi.org/10.1098/rspb.2016.2562.

Testo completo

Abstract (sommario):

Why is drug resistance common and vaccine resistance rare? Drugs and vaccines both impose substantial pressure on pathogen populations to evolve resistance and indeed, drug resistance typically emerges soon after the introduction of a drug. But vaccine resistance has only rarely emerged. Using well-established principles of population genetics and evolutionary ecology, we argue that two key differences between vaccines and drugs explain why vaccines have so far proved more robust against evolution than drugs. First, vaccines tend to work prophylactically while drugs tend to work therapeutically. Second, vaccines tend to induce immune responses against multiple targets on a pathogen while drugs tend to target very few. Consequently, pathogen populations generate less variation for vaccine resistance than they do for drug resistance, and selection has fewer opportunities to act on that variation. When vaccine resistance has evolved, these generalities have been violated. With careful forethought, it may be possible to identify vaccines at risk of failure even before they are introduced.

Gli stili APA, Harvard, Vancouver, ISO e altri

18

Croft, Simon L., Shyam Sundar e Alan H. Fairlamb. "Drug Resistance in Leishmaniasis". Clinical Microbiology Reviews 19, n. 1 (gennaio 2006): 111–26. http://dx.doi.org/10.1128/cmr.19.1.111-126.2006.

Testo completo

Abstract (sommario):

SUMMARY Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs has been used for over 60 years for leishmaniasis treatment, it is only in the past 2 years that the mechanisms of action and resistance have been identified, related to drug metabolism, thiol metabolism, and drug efflux. With the introduction of new therapies, including miltefosine in 2002 and paromomycin in 2005-2006, it is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.

Gli stili APA, Harvard, Vancouver, ISO e altri

19

de Koning, Harry P. "Drug resistance in protozoan parasites". Emerging Topics in Life Sciences 1, n. 6 (22 dicembre 2017): 627–32. http://dx.doi.org/10.1042/etls20170113.

Testo completo

Abstract (sommario):

As with all other anti-infectives (antibiotics, anti-viral drugs, and anthelminthics), the limited arsenal of anti-protozoal drugs is being depleted by a combination of two factors: increasing drug resistance and the failure to replace old and often shamefully inadequate drugs, including those compromised by (cross)-resistance, through the development of new anti-parasitics. Both factors are equally to blame: a leaking bathtub may have plenty of water if the tap is left open; if not, it will soon be empty. Here, I will reflect on the factors that contribute to the drug resistance emergency that is unfolding around us, specifically resistance in protozoan parasites.

Gli stili APA, Harvard, Vancouver, ISO e altri

20

Kurt Yilmaz, Nese, e Celia A. Schiffer. "Introduction: Drug Resistance". Chemical Reviews 121, n. 6 (24 marzo 2021): 3235–37. http://dx.doi.org/10.1021/acs.chemrev.1c00118.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

21

Emery, VC. "Cytomegalovirus Drug Resistance". Antiviral Therapy 3, n. 4 (maggio 1998): 239–42. http://dx.doi.org/10.1177/135965359800300403.

Testo completo

Abstract (sommario):

Clinical resistance of cytomegalovirus (CMV) against the currently licensed antiviral drugs is becoming an increasingly recognized problem. This review focuses on the molecular basis of resistance and describes mutations in the UL54 DNA polymerase leading to resistance against cidofovir, foscarnet and ganciclovir. The review highlights two important developments in our appreciation of resistance. Firstly, the use of more rapid molecular based assays to detect genotypic resistance and secondly, the relationship between resistance profiles in multiple organ systems of the same host. Finally, the changing face of CMV disease in the era of highly active antiviral chemotherapy is considered with respect to its impact on the frequency of CMV resistance in the clinic.

Gli stili APA, Harvard, Vancouver, ISO e altri

22

Clavel, François, e Allan J. Hance. "HIV Drug Resistance". New England Journal of Medicine 350, n. 10 (4 marzo 2004): 1023–35. http://dx.doi.org/10.1056/nejmra025195.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

23

Richman, D. D. "HIV Drug Resistance". Annual Review of Pharmacology and Toxicology 33, n. 1 (aprile 1993): 149–64. http://dx.doi.org/10.1146/annurev.pa.33.040193.001053.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

24

Davies, Peter, e Damian Cullen. "Antituberculosis drug resistance". Clinical Medicine 9, n. 1 (1 febbraio 2009): 91.1–91. http://dx.doi.org/10.7861/clinmedicine.9-1-91.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

25

Perrin, Luc. "Drug resistance mutations". AIDS 18, n. 8 (maggio 2004): 1201–2. http://dx.doi.org/10.1097/00002030-200405210-00014.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

26

White, Nicholas J. "Antimalarial drug resistance". Journal of Clinical Investigation 113, n. 8 (15 aprile 2004): 1084–92. http://dx.doi.org/10.1172/jci21682.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

27

Tesio, Melania. "Starving Drug Resistance". HemaSphere 4, n. 6 (10 novembre 2020): e495. http://dx.doi.org/10.1097/hs9.0000000000000495.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

28

Pizzorno, Andrés, Yacine Abed e Guy Boivin. "Influenza Drug Resistance". Seminars in Respiratory and Critical Care Medicine 32, n. 04 (agosto 2011): 409–22. http://dx.doi.org/10.1055/s-0031-1283281.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

29

COEN, DONALD M. "Antiviral Drug Resistance". Annals of the New York Academy of Sciences 616, n. 1 AIDS (dicembre 1990): 224–36. http://dx.doi.org/10.1111/j.1749-6632.1990.tb17843.x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

30

Weitzman, Jonathan B. "Cancer drug resistance". Genome Biology 2 (2001): spotlight—20010626–01. http://dx.doi.org/10.1186/gb-spotlight-20010626-01.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

31

Flintoff, Wayne F. "Acquired drug resistance". Genome 31, n. 1 (1 gennaio 1989): 447. http://dx.doi.org/10.1139/g89-073.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

32

Gold, Howard S., e Robert C. Moellering. "Antimicrobial-Drug Resistance". New England Journal of Medicine 335, n. 19 (7 novembre 1996): 1445–53. http://dx.doi.org/10.1056/nejm199611073351907.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

33

Phelps, Charles E. "Bug/Drug Resistance". Medical Care 27, n. 2 (febbraio 1989): 194–203. http://dx.doi.org/10.1097/00005650-198902000-00009.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

34

Robertson, John D. "CANCER DRUG RESISTANCE". Shock 26, n. 6 (dicembre 2006): 638. http://dx.doi.org/10.1097/01.shk.0000248599.09507.90.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

35

RICHMAN, DOUGLAS D. "HIV Drug Resistance". AIDS Research and Human Retroviruses 8, n. 6 (giugno 1992): 1065–71. http://dx.doi.org/10.1089/aid.1992.8.1065.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

36

Schmit, Jean-Claude. "HIV drug resistance". HIV Clinical Trials 3, n. 3 (maggio 2002): 225–26. http://dx.doi.org/10.1310/kmkn-ke48-2gwu-g0he.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

37

Richman, Douglas D. "Viral drug resistance". Current Opinion in Infectious Diseases 3, n. 6 (dicembre 1990): 819–23. http://dx.doi.org/10.1097/00001432-199012000-00014.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

38

Loeffler, Juergen, e David A. Stevens. "Antifungal Drug Resistance". Clinical Infectious Diseases 36, Supplement_1 (15 gennaio 2003): S31—S41. http://dx.doi.org/10.1086/344658.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

39

Richman, Douglas D. "Antiviral drug resistance". Antiviral Research 71, n. 2-3 (settembre 2006): 117–21. http://dx.doi.org/10.1016/j.antiviral.2006.03.004.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

40

Calmy, Alexandra, Fernando Pascual e Nathan Ford. "HIV Drug Resistance". New England Journal of Medicine 350, n. 26 (24 giugno 2004): 2720–21. http://dx.doi.org/10.1056/nejm200406243502621.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

41

Pillay, D., e A. M. Geddes. "Antiviral drug resistance". BMJ 313, n. 7056 (31 agosto 1996): 503–4. http://dx.doi.org/10.1136/bmj.313.7056.503.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

42

Richman, Douglas D. "Antiretroviral drug resistance". AIDS 5, Supplement (gennaio 1991): 189. http://dx.doi.org/10.1097/00002030-199101001-00027.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

43

Richman, Douglas D. "HIV DRUG RESISTANCE". AIDS 8, Supplement 4 (novembre 1994): S3. http://dx.doi.org/10.1097/00002030-199411004-00010.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

44

STEVENSON, AUDREY M. "Emerging Drug Resistance". MCN, The American Journal of Maternal/Child Nursing 23, n. 4 (luglio 1998): 216. http://dx.doi.org/10.1097/00005721-199807000-00010.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

45

Pillay, D., e M. Zambon. "Antiviral drug resistance". BMJ 317, n. 7159 (5 settembre 1998): 660–62. http://dx.doi.org/10.1136/bmj.317.7159.660.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

46

Field, Hugh J., e Siân E. Goldthorpe. "Antiviral drug resistance". Trends in Pharmacological Sciences 10, n. 8 (agosto 1989): 333–37. http://dx.doi.org/10.1016/0165-6147(89)90069-2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

47

Dannenberg, Jan-Hermen, e Anton Berns. "Drugging Drug Resistance". Cell 141, n. 1 (aprile 2010): 18–20. http://dx.doi.org/10.1016/j.cell.2010.03.020.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

48

Hampton, Tracy. "Cancer Drug Resistance". JAMA 309, n. 1 (2 gennaio 2013): 20. http://dx.doi.org/10.1001/jama.2012.173440.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

49

McCloskey, William W. "Microbial Drug Resistance". JAMA: The Journal of the American Medical Association 278, n. 6 (13 agosto 1997): 523. http://dx.doi.org/10.1001/jama.1997.03550060099047.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

50

Hampton, Tracy. "Melanoma Drug Resistance". JAMA 296, n. 4 (26 luglio 2006): 384. http://dx.doi.org/10.1001/jama.296.4.384-b.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!